SAN DIEGO, June 16, 2022 (GLOBE NEWSWIRE) -- Lenire Biosciences Inc., a biopharmaceutical company developing novel treatments for Fragile X Syndrome (FXS) and related disorders, today announced that it has agreed to a license from UCL (University College London) for VSN16R, a small molecule positive modulator of large-conductance, calcium-activated potassium (“BK”) channels, as a novel therapy for FXS. The development of this technology was supported by UCL Business (UCLB), the commercialization company of UCL.

FXS is a rare, inherited condition that can cause issues including developmental delays, learning and behavioural difficulties, physical abnormalities, anxiety, attention or hyperactivity disorders and autism spectrum disorder. FXS has been detected in all populations and ethnic groups and recent estimates suggest a prevalence of approximately 1 in 4,000 males and 1 in 8,000 females have FXS.1

VSN16R is an orally bioavailable compound based on anandamide, a natural signalling molecule in the endocannabinoid system in humans. It was developed in the laboratory of Professor David Selwood (Wolfson Institute for Biomedical Research, UCL), as part of a study that has completed phase II human trials for muscle stiffness and involuntary muscle spasms in multiple sclerosis, a common symptom known as spasticity. A large and diverse set of preclinical studies have implicated deficient BK channel activity in the etiology of FXS, and recent studies in a mouse model of the syndrome demonstrated efficacy of VSN16R in rescuing FXS-related phenotypes. Lenire plans to develop VSN16R to treat patients with FXS.

“Extensive research into the role of altered BK channel expression, activity and regulation in FXS models provides a strong rationale for pharmacologically augmenting its activity as a disease-modifying treatment for FXS that may improve many of its core symptoms,” shared Dr. Peter Vanderklish, co-founder of Lenire.

FXS is the most prevalent inherited form of intellectual disability and a leading cause of autism spectrum disorder. There are currently no disease-modifying therapies for FXS, and some of the most problematic symptoms, such as anxiety, are largely refractory to medications that would be used to treat them in the neurotypical population.

Dr. Craig Erickson, Professor of Psychiatry at Cincinnati Children’s Hospital Medical Center and Director of the Cincinnati Fragile X Research and Treatment Center commented, “We are excited to collaborate with Lenire to test VSN16R in patients with FXS.”

Professor David Selwood commented, "The effect of our drug in the disease models is transformative; we are very excited to see this drug go forward to the clinic in people with Fragile X."

Lenire Biosciences is privately held, clinical stage biopharmaceutical company that is developing novel, patent protected therapeutics for the treatment of Fragile X Syndrome (FXS), a leading cause of intellectual disability world-wide that also presents with anxiety, attention deficit, hyperactivity, autism spectrum behaviors and other disabling symptoms. More information on the Company can be viewed at https://lenirebiosciences.com.

David H. Crean Chief Executive Officer david@lenirebiosciences.com 858-461-9490

_________________________ 1 FRAXA Research Foundation (https://www.fraxa.org)

As we close in on the final quarter of 2022, investors are looking for an answer to one question: was June’s low the bottom for stocks, or do they have more room to fall? It’s a serious question, and there may be no easy answer. Markets are facing a series of headwinds, from the high inflation and rising interest rates that we’ve grown familiar with to an increasingly strong dollar that will put pressure on the upcoming Q3 earnings. Weighing in on current conditions from Charles Schwab, the $8 t

Congressional Democrats want to slam shut a tax loophole known as the "backdoor" Roth IRA. In one of several proposed changes that target the retirement accounts of wealthy Americans, Democrats on the House Ways and Means Committee want to prohibit people … Continue reading → The post Democrats Want to End This Lucrative Retirement Account Loophole appeared first on SmartAsset Blog.

Republican lawmakers warned Apple Inc (NASDAQ: AAPL) against intense scrutiny lest it procured memory chips from controversial Chinese semiconductor manufacturer Yangtze Memory Technologies Co for the new iPhone 14, the Financial Times reports. The lawmakers expressed alarm at reports suggesting Apple would add the Yangtze to its list of suppliers for Nand flash memory chips meant for storing data on smartphones. Apple acknowledged not using YMTC chips in products and evaluated sourcing from YMT

The S&P 500 is on again, off again all year. But investors clearly have a "buy list" of stocks they want to own when the rally looks real.

NIO Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NIO performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.

Berkshire Hathaway is on pace to collect $6.07 billion in dividend income over the next 12 months. Just five holdings will account for 71% of total payouts.

It's time to be extra picky.

The EARN Act is the latest addition to the lineup of proposals legislators have put forth to bolster retirement savings. Senators Ron Wyden, a Democrat from Oregon, and Mike Crapo, a Republican from Idaho, introduced the Enhancing American Retirement Act on Thursday. “Americans deserve dignified retirements after decades of hard work, and our bill is an important step forward,” Wyden said in a statement.

A strong bearish trend defined the markets in the first half of the year; since then, the key point has been volatility. Stocks hit a bottom back in June, when the S&P 500 dropped into the 3,600s. That has proven to be a support level in the last two months, and at least one strategist believes that the market won’t be testing those lows again this year. JPMorgan's Jason Hunter believes that inflation may have peaked, and that the upcoming CPI report will provide additional evidence of that. “We

Expect cost certainty to fly right out the (drafty) window.

BullsEyeOption.com Chief Market Strategist Alan Knuckman joins Yahoo Finance Live to discuss energy markets and how Europe's energy crisis could impact both the U.S. and China.

Investors are seeing higher growth potential for QuantumScape's battery cell technology after an interesting EV industry development.

On Friday, the company unveiled the Robinhood Investor Index, which captures how customers invest based on the top 100 most owned stocks on the platform.

(Bloomberg) -- In a week that saw discretionary buyers beat a quick retreat from risky assets, another set of traders stood up to halt a three-week plunge in the S&P 500: those with little choice but to buy.Most Read from BloombergCharles Becomes King as the Face of a Nation ChangesDouble Rainbow Appears Over Buckingham Palace as Crowd Gathers to Mourn QueenUkraine Army’s Breakthrough in North Threatens Russian GripQueen Elizabeth’s Doctors Are Concerned for Her HealthQueen Elizabeth II, Britain

Nio (NYSE: NIO) reported increasing losses in its second-quarter earnings report this week, but investors are shrugging that off, sending shares soaring Friday morning. Although its profit margins have been on a downward trend, new models being launched could turn that around in the coming years. Consumer prices in China increased at a slower pace than many expected in August, and producer inflation sank to the lowest level since February 2021, reports Reuters.

AT&T income-hungry shareholders should have seen it coming. In April last year, a month before announcing the spinoff of its media division to shareholders in the form of shares of a 71% stake in the newly created Warner Bros. Discovery Chief Executive Officer John Stankey assured investors that “our deliberate capital-allocation plan allowed us to invest and sustain our dividend at current levels, which we believe is attractive.” AT&T’s eventual failure to raise the dividend in 2021 broke a 34-year streak and saw it booted out of the vaunted S&P 500 Dividend Aristocrats Index.

The old saying “different strokes for different folks” certainly rings true in the stock market. Some investors prefer growth stocks like Tesla Inc. that are volatile but have produced years of outstanding appreciation. Other folks prefer less volatile stocks like Johnson & Johnson whose growth may be slower but also add dividends of 2% to 3% annually to the total performance. In addition, there are income investors, who strictly look for stocks that will provide high-yield dividends year after

In this article, we will look at 10 stocks that Jim Cramer is talking about in September. If you want to explore more stocks that journalist investor, Jim Cramer, is talking about in September, you can also take a look at Jim Cramer is Talking About These 5 Stocks in September. Jim Cramer has acquired […]

These highly innovative companies are begging to be bought following a peak decline of 34% in the Nasdaq Composite.

Deciding when to time your retirement plan withdrawals matters for determining how long your money will last and what you'll pay in taxes for those distributions. If you have a 401(k) at work, you might follow the Rule of 55 … Continue reading → The post Rule of 55 vs. 72(t): Retirement Plan Withdrawals appeared first on SmartAsset Blog.